This is a remote position for those based in Ireland, or on the East Coast of the US. We have an office in Cardiff (UK), lab operations in New York and Salt Lake City (US) and a tech-focused hub in Kilkenny (Ireland).
We are looking for a Senior Data Engineer to design, build, and maintain our data infrastructure and warehouse. As a Senior Data Engineer, you will be responsible for integrating multiple data sources, including Electronic Health Record (EHR) information, into our data pipeline facilitating both real-time and project-based data analysis and reporting.
RenalytixAI was established in 2018 with the vision of providing advanced technology solutions to drive improvements in kidney health for millions of patients worldwide. KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics, and extensive personalized patient data from the electronic health record, or EHR, systems, to generate a unique patient risk score.
This patient risk score enables the prediction of adverse kidney outcomes in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
As a Senior Data Engineer at RenalytixAI, you will:
The ideal candidate will have…
As one of the first hires into the data team, there will be a lot of scope to grow with the company as we embark on a rapid growth trajectory over the next 18 months. As our clients include some of the largest health systems in the United States, you will be working closely with experts across the industry. You will also become an integral part of our implementation team as we roll out to future clients, growing our portfolio of data-driven products and health technology solutions.
RenalytixAI was established in 2018 with the vision of providing advanced technology solutions to drive improvements in kidney health for millions of patients worldwide. These solutions combine deep clinical and scientific research, extensive data sets and artificial intelligence methodologies into integrated software platforms designed to provide patients, clinicians, health systems and payors with unique insights to ensure the best possible clinical care is provided where and when it is required.
Specifically, we are a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and significantly lower healthcare costs.
KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and extensive personalized patient data from the electronic health record, or EHR, systems, to generate a unique patient risk score.
This patient risk score enables prediction of adverse kidney outcomes in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
CKD affects approximately 37 million individuals in the United States, significantly impacting their quality of life and resulting in Medicare spending of at least $114 billion per year. In response to this substantial kidney disease burden, a U.S. Presidential Executive Order on Advancing American Kidney Health was issued in July 2019 to support comprehensive change in kidney disease care.
The company is listed on the London Stock Exchange (LSE.RENX) and NASDAQ (RNLX) and has laboratory operations in New York City and Salt Lake City with offices in Cardiff UK and Kilkenny Ireland.